Vistagen Therapeutics, Inc.
VTGN· Nasdaq
VTGNVistagen Therapeutics, Inc.
Filed Aug 14, 2013 · 10-Q · 45 days after period end · 0001415889-13-001620
| Metric | Q1 2014 | Q1 2011 | Q1 2010 |
|---|---|---|---|
| Revenue | — | $555.00K | $733.92K |
| Net Income | $185.70K | -$2.41M | -$981.63K |
| EPS Diluted | -$0.02 | -$0.22 | -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Jun 30, 2013 · filed Aug 14, 2013 · 45 d after period end
